This site uses cookies: find out more.
Published: 14th April 2011
Dashboard: 17th Conference of Clinical Oncology – Study of an extract of Nerium oleander, Anvirzel™, in prostate and breast cancer cell lines
Authors: Apostolou P., Toloudi M., Chatziioannou M., Papasotiriou I.
Find out more about the science behind RGCC tests
Read moreNo, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.
Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.
The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.
Online consultations will give you the opportunity to speak to any member of the RGCC Network at a time and place that is convenient to you. You will be able to choose from a shortlist of clinicians who best suit your needs. The online consultation will be available via the Cancer A-Z app soon… please keep checking the app for updates.
Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.
Didn't find an answer to your question? Contact us directly.
Get in touchRGCC operates in 23 countries across the world, with bases in all five continents.
Find out more